Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
24/09/2026
aTyr Pharma aligned with FDA on Phase 3 study of efzifitimod in pulmonary sarcoidosis (Ref)
aTyr Pharma reached alignment with the US FDA on the Ph3 protocol for efzofitimod (an immunomodulator) in patients with chronic symptomatic pulmonary sarcoidosis with restrictive lung disease.
The company will initially focus on regulatory submissions in the US and EU
Study-related activities are expected to initiate in Q4 of 2026.
Kyverna reported 1-year data for miv-cel in SPS and gMG (Ref)
Kyverna Therapeutics reported positive 1-year topline data for miv-cel (mivocabtagene autoleucel; KYV-10; CD19 CAR-T ) from registrational Ph2 KYSA-8 trial in stiff person syndrome (SPS) and long-term follow-up from registrational KYSA-6 trial in generalized myasthenia gravis (gMG).
Miv-cel demonstrated durable clinical improvements through 1year across both indications, with patients remaining free of chronic immunosuppressive therapy.
No high-grade CRS, ICANS, or IEC-HS was reported, supporting a favorable safety profile.
Kyverna plans a rolling BLA submission for SPS in Q4 2026 and expects to complete Phase 3 gMG enrollment in mid-2027.


